Expanded Access Program for the potential use of PLX cells in the treatment of Single Patient suffering from complications associated with COVID-19
Latest Information Update: 03 Apr 2023
At a glance
- Drugs COVID-19 infection therapeutics Charite University of Medicine Berlin/Pluristem Therapeutics (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections; Respiratory insufficiency
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Pluri
- 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
- 14 May 2020 According to a Pluristem Therapeutics media release, 1 patient has completed a 28-day follow up period.
- 14 May 2020 Results presented in the Pluristem media release.